Breast Cancer

GLP-1 receptor agonist use was tied to reduced HR+/HER2− breast cancer incidence and improved overall survival in nondiabetic women with elevated BMI.

First-line sacitizumab govitecan plus pembrolizumab prolonged PFS2 PD-L1+ metastatic triple-negative breast cancer.

Patients with breast cancer experienced improvement in vasomotor symptoms when treated with elinzanetant, irrespective of type of endocrine therapy.

Switching to camizestrant plus CDK4/6i upon ESR1 mutation detection demonstrated a PFS of 7.6 months and achieved significant PFS2 benefit in SERENA-6.

Giredestrant plus palbociclib improved PFS numerically but not significantly vs letrozole plus palbociclib in 1L ER+, HER2– mBC.

Findings from the I-SPY 2.2 trial may show an important step toward treatment de-escalation for certain patients with HER2-negative breast cancer.

Data from the VIKTORIA-1 trial support the PAM pathway as a molecular driver in HR-positive, HER2-negative breast cancer of any PIK3CA mutation status.

Data from the PANKU-Breast02 trial may support iza-bren as a new standard of care in this TNBC population.

For patients with early breast cancer receiving chemotherapy, the use of a dexamethasone mouthwash did not significantly reduce the incidence of oral mucositis.

Final analysis of KEYNOTE-522 confirms pembrolizumab plus chemotherapy improves event-free and overall survival in high-risk early-stage TNBC.

Sacituzumab govitecan plus pembrolizumab maintained PFS improvements vs chemotherapy plus pembrolizumab in first-line metastatic TNBC.

Results from the phase 3 lidERA Breast Cancer trial demonstrated a 35% reduction in the risk of invasive disease or death with giredestrant in this breast cancer population.

The assay may identify a group comprising approximately two-thirds of patients who do not have a meaningful chance of benefit from adjuvant chemotherapy.

Patients with breast cancer and macrometastases who omitted axillary lymph node dissection experienced noninferior survival compared with those who didn’t.

Community-clinic data shows real-world EFS and pCR closely match KEYNOTE-522, strengthening confidence in real-world endpoints for eTNBC care.

Gedatolisib combinations significantly extend progression-free survival after CDK4/6 inhibitor failure in HR+/HER2– breast cancer, with manageable adverse effects and stable quality of life.

The FDA extends camizestrant review. Plus, promising Bria-IMT survival data and a ctDNA blood test that spots breast cancer recurrence 4 years early.

Leading experts preview highly anticipated breast cancer data at ASCO 2026, including readouts from the SERENA-6, persevERA, and OPTIMA trials.